KalVista Pharmaceuticals (KALV) Equity Average: 2015-2024
Historic Equity Average for KalVista Pharmaceuticals (KALV) over the last 6 years, with Dec 2024 value amounting to $149.2 million.
- KalVista Pharmaceuticals' Equity Average was N/A to $149.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $149.2 million, marking a year-over-year change of. This contributed to the annual value of $90.2 million for FY2020, which is 45.57% up from last year.
- Per KalVista Pharmaceuticals' latest filing, its Equity Average stood at $149.2 million for Q4 2024, which was down 2.75% from $153.4 million recorded in Q4 2024.
- KalVista Pharmaceuticals' Equity Average's 5-year high stood at $189.7 million during Q3 2024, with a 5-year trough of $61.8 million in Q1 2021.
- In the last 2 years, KalVista Pharmaceuticals' Equity Average had a median value of $147.6 million in 2024 and averaged $138.2 million.
- As far as peak fluctuations go, KalVista Pharmaceuticals' Equity Average crashed by 34.12% in 2021, and later skyrocketed by 91.70% in 2024.
- Over the past 4 years, KalVista Pharmaceuticals' Equity Average (Quarterly) stood at $69.7 million in 2020, then tumbled by 34.12% to $61.8 million in 2021, then reached $126.9 million in 2023, then rose by 20.89% to $149.2 million in 2024.
- Its Equity Average stands at $149.2 million for Q4 2024, versus $153.4 million for Q4 2024 and $189.7 million for Q3 2024.